London, 16 July 2025 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it remains a constituent of the FTSE4Good Index Series, affirming its strong environmental, social and governance practices.

The FTSE4Good Index Series was created by the global index and data provider FTSE Russell to highlight companies that demonstrate good sustainability practices and to support investors that wish to align their portfolios with such organisations.

Hikma has been a member of the FTSE4Good Index since 2014. Throughout this period, Hikma has made significant progress by embedding sustainability into its corporate strategy and reinforcing its commitment to providing access to high-quality generic medicines, with 262 million patients treated globally in 2024.

Placing access to medicines at the heart of our purpose, Hikma empowers its people, protects the environment, and acts with unwavering integrity.

Tim Brooks, VP Sustainability for Hikma, commented, “We are pleased to remain constituents of the FTSE4Good,  recognising our ongoing commitment to ensure access to high-quality medicines across our regions in North America, Europe, and MENA. Enabling access to essential medicines is our top priority, underpinning our efforts to promote more sustainable business practices and aligning with our purpose of putting better health within reach, every day.”

For more information on how Hikma acts responsibly, including details of the targets Hikma has set, visit our website https://www.hikma.com/acting-responsibly/ and read our 2024 Sustainability Report https://www.hikma.com/responsibility/sustainability-reports/